biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~70 kDa
species reactivity
mouse, human, rat
concentration
~1.5 mg/mL
technique(s)
immunoprecipitation (IP): 15-30 μg using rat brain extracts (S1 fraction), indirect immunofluorescence: 10-20 μg/mL using HeLa cells expressing human gigaxonin, western blot: 1-2 μg/mL using mouse brain extracts (S1 fraction), and 1.5-3 μg/mL using SH-SY5Y cell lysates, western blot: 1.5-3 μg/mL using SH-SY5Y cell lysates
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... GAN(8139)
mouse ... Gan(209239)
rat ... Gan(307893)
General description
Gigaxonin (GAN) is encoded by the gene mapped to human chromosome 16q23.2. The encoded protein is characterized with an N-terminal BTB (for broad-complex, ramtrack and bric a brac) domain followed by a six kelch repeats, which are predicted to adopt a β-propeller shape.8
Application
Anti-Gigaxonin (N-terminal) antibody produced in rabbit has been used in immunofluorescence and immunoblotting assay.
Biochem/physiol Actions
Gigaxonin (GAN) acts as a key regulator of intermediate filaments (IFs) and the microtubule-associated protein 1B (MAP1B) light chain degradation, which is required for neuronal survival. GAN contributes to neurofilament architecture. Additionally, it also influences the ubiquitination and degradation of some proteins. Mutation in the gene is associated with the development of giant axonal neuropathy.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Electronic medical records and genomics (eMERGE) network exploration in cataract: Several new potential susceptibility loci
Ritchie MD
Molecular Vision, 20, 1281-1295 (2014)
The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy
Bomont P
Nature Genetics, 26, 370-374 (2000)
Novel homozygous missense mutation in GAN associated with Charcot-Marie-Tooth disease type 2 in a large consanguineous family from Israel
Aharoni S
BMC Medical Genetics, 17, 82-82 (2016)
Rachel M Bailey et al.
Molecular therapy. Methods & clinical development, 9, 160-171 (2018-05-17)
An NIH-sponsored phase I clinical trial is underway to test a potential treatment for giant axonal neuropathy (GAN) using viral-mediated GAN gene replacement (https://clinicaltrials.gov/ct2/show/NCT02362438). This trial marks the first instance of intrathecal (IT) adeno-associated viral (AAV) gene transfer in humans.
Po-Han Chen et al.
JCI insight, 5(1) (2020-01-17)
Gigaxonin (also known as KLHL16) is an E3 ligase adaptor protein that promotes the ubiquitination and degradation of intermediate filament (IF) proteins. Mutations in human gigaxonin cause the fatal neurodegenerative disease giant axonal neuropathy (GAN), in which IF proteins accumulate
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持